Ignite Creation Date:
2024-05-06 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 2:25 PM
Study NCT ID:
NCT05253807
Status:
COMPLETED
Last Update Posted:
2023-11-21
First Post:
2022-02-14
Brief Title:
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
Sponsor:
Incyte Corporation
Organization:
Incyte Corporation
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-04-29
Start Date Type:
ACTUAL
Primary Completion Date:
2023-08-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-08-16
Completion Date Type:
ACTUAL
First Submit Date:
2022-02-14
First Submit QC Date:
February 23 2022
Study First Post Date:
2022-02-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-10
Last Update Post Date:
2023-11-21
Last Update Post Date Type:
ACTUAL